Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Brown University
Swiss Cancer Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Wake Forest University Health Sciences
Georgetown University
University of Iowa
Memorial Sloan Kettering Cancer Center
Stanford University
Mayo Clinic
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Fundación GECP
Yonsei University
University of Nebraska
University of Utah
Seoul National University Hospital
Fundación GECP
Montefiore Medical Center
University of Leeds
Mario Negri Institute for Pharmacological Research
Memorial Sloan Kettering Cancer Center
Abramson Cancer Center at Penn Medicine
University of Kentucky
Washington University School of Medicine
M.D. Anderson Cancer Center
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intergroupe Francophone de Cancerologie Thoracique
Swiss Cancer Institute
Jonsson Comprehensive Cancer Center
Alliance Foundation Trials, LLC.
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rush University Medical Center
University of Birmingham
M.D. Anderson Cancer Center
Stanford University
University of Texas Southwestern Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Latin American Cooperative Oncology Group
University Health Network, Toronto
Dutch Society of Physicians for Pulmonology and Tuberculosis
University of Texas Southwestern Medical Center
The Netherlands Cancer Institute
Indiana University
University of Michigan Rogel Cancer Center
University of British Columbia
Emory University